Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 18/20 | 0.69 |
| ▸ | FNTB | P49356 | 18/20 | 0.69 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.69 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5023612 | 0.93 | FNTA (0.70) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL6303247 | 0.88 | FNTA (0.79) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL14570643 | 0.88 | FNTA (0.67) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL5023704 | 0.85 | FNTA (0.69) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL14570642 | 0.85 | FNTA (0.67) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL5023789 | 0.84 | FNTA (0.68) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL5022769 | 0.83 | FNTA (0.81) | FNTAFNTBPGGT1B | |
| SCHEMBL1683527 | 0.82 | FNTA (1.00) | FNTAFNTBPGGT1B | |
| SCHEMBL14570640 | 0.81 | FNTA (0.64) | FNTAFNTBPGGT1BRORC | |
| SCHEMBL5016840 | 0.80 | FNTA (0.78) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322650-B1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | claimed |
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-06 | — | — | US | claimed |
| EP-1322650-B1 | FARNESYL TRANSFERASE INHIBITING 6-HETEROCYCLYLMETHYL QUINOLINE AND QUINAZOLINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-24 | — | — | EP | disclosed |
| US-7196094-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196094-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-7196094-B2 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207887-A1 | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives | FNTA, FNTB, RCE1 | FNTA 1/4885FNTB 2/4885PGGT1B 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.